ALTRI BIOTHERAPEUTICS

Altri is a pre-clinical-stage pharmaceutical company focusing on the development of therapeutic monoclonal antibodies (mAbs) and is located in Richmond, VA, in the VA Bio+Tech Park... Altri has built on 30 years of research on the insulin-like growth factor (IGF) signaling system to develop agonistic mAbs to use this system for cancer treatment. Altri has licensed the patents for targeting the IGFBP-3/TMEM219 pathway for the treatment of human diseases from Virginia Commonwealth University for all indications globally. Altri's initial target is directed at TNBC, but Altri plans to use the same antibody therapeutics approach to develop related agonistic mAbs targeting metastatic and invasive cancers including lung, colon, pancreatic and liver cancer, melanoma and leukemia. Altri has also filed additional patents for the protection of the use of agonistic mAbs for other indications including cancer and inflammatory diseases... Altri established strong preclinical anticancer efficacy..

Primary location: Richmond United States